NEW HAVEN, Conn.--(BUSINESS WIRE)--
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Judith
A. Reinsdorf, J.D., has been appointed to the Company's Board of
Directors. Ms. Reinsdorf is an accomplished executive with a strong
background in corporate governance and broad expertise in managing
corporate and legal affairs for large public companies.
Ms. Reinsdorf until recently served as Executive Vice President and
General Counsel of Johnson Controls International, a global
leader in building products and technology, integrated solutions, and
energy storage, following its merger in September 2016 with Tyco
International, where she served as Executive Vice President and General
Counsel from March 2007 until September 2016. Previously, she served as
Vice President, General Counsel and Secretary of C. R. Bard, Inc., as
Vice President and Corporate Secretary of Tyco, as Vice President and
Associate General Counsel of Pharmacia Corporation, and as Assistant
General Counsel and Chief Legal Counsel, Corporate, at Monsanto Company.
Ms. Reinsdorf currently serves on the Board of Directors of Dun &
Bradstreet, a publicly traded data and analytics company. She earned her
bachelor's degree from the University of Rochester and her J.D. from
Cornell Law School.
David Brennan, Chairman of the Board, commented, "We are pleased to
welcome Judy to Alexion's Board of Directors. Judy brings strong
corporate governance and legal expertise, with a proven track record in
global compliance, strategic planning, data privacy, and regulatory
matters. Her broad experience at large U.S. public companies, both
within and outside the healthcare industry, will be a valuable addition
to our board."
Ms. Reinsdorf added: "I am excited to join Alexion's Board of Directors
at a pivotal time for the Company as it executes on a strategy to
deliver sustainable growth and strengthens its leadership position in
rare diseases. I look forward to applying my experience to help guide
Alexion's future success."
Alexion also announced today that Director Ann M. Veneman, J.D., has
advised the Board that she does not plan to stand for re-election at the
Company's next annual meeting of shareholders and will be retiring from
the Board following eight years of service as an Alexion director. As
previously announced, Directors M. Michele Burns and Alvin S. Parven
have also both advised the Board that they do not plan to stand for
re-election at the Company's next annual meeting of shareholders.
Alexion is a global biopharmaceutical company focused on serving
patients and families affected by rare diseases through the innovation,
development and commercialization of life-changing therapies. Alexion is
the global leader in complement inhibition and has developed and
commercializes the first and only approved complement inhibitor to treat
patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical
hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR)
antibody-positive generalized myasthenia gravis (gMG). In addition,
Alexion has two highly innovative enzyme replacement therapies for
patients with life-threatening and ultra-rare metabolic disorders,
hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). As
the leader in complement biology for over 20 years, Alexion focuses its
research efforts on novel molecules and targets in the complement
cascade, and its development efforts on the core therapeutic areas of
hematology, nephrology, neurology, and metabolic disorders. This press
release and further information about Alexion can be found at: www.alexion.com.
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. These
forward-looking statements often include words such as "anticipate,"
"believe," "expect," "will," or similar expressions. Forward-looking
statements are subject to factors that may cause Alexion's results and
plans to differ from those expected, including the risks set forth from
time to time in Alexion's filings with the U.S. Securities and Exchange
Commission, including but not limited to the risks discussed in
Alexion's Quarterly Report on Form 10-Q for the period ended September
30, 2017 and in our other filings with the U.S. Securities and Exchange
Commission. Alexion does not intend to update any of these
forward-looking statements to reflect events or circumstances after the
date hereof, except when a duty arises under law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180205005813/en/
Alexion Pharmaceuticals, Inc.
Kim Diamond, 475-230-3775
Director, Corporate Communications
Ridloff, CFA, 475-230-3601
Vice President, Investor Relations
Director, Investor Relations
Source: Alexion Pharmaceuticals, Inc.
News Provided by Acquire Media